drugset / Trial / NCT07268040

A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors

NCT07268040

Phase 2 Recruiting 400 enrolled Shanghai Hengrui Pharmaceutical Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study aims to evaluate the safety, tolerability and efficacy of SHR-7787 in combination with other anti-tumor drugs in patients with malignant solid tumors.

Timeline

Start
2025-12-23
Primary completion
2028-12
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Adebrelimab Monoclonal antibody
Subject BP102 Monoclonal antibody
Subject Carboplatin Small molecule
Subject Cisplatin Other / unclassified
Subject Etoposide Small molecule
Subject SHR-4849 Unknown
Subject SHR-7787 Unknown

Indications